Eli Lilly's experimental GLP-1 pill shows promise in a Phase Three trial, helping users lose an average of 12% of body weight, potentially transforming diabetes and obesity treatment.

A growing wave of lawsuits is targeting Novo Nordisk, the manufacturer of the widely used drugs Ozempic and Wegovy, following ...

Glucagon-like peptide-1 (GLP-1) receptor agonists show promise in reducing hidradenitis suppurativa severity and pain, ...

Glucagon-like peptide 1 receptor agonists, including semaglutide, have increased in use and will continue to increase due to their effectiveness in weight loss.

Mounjaro prices are to double on September 1 says the pharmaceutical giant that makes the weight loss jab. The 15mg pen is expected to cost ...

Many Mounjaro users are looking into alternative medications following news of a 170 percent price increase in the UK ...

Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist taken as a ...

She recommends women undergo a “baseline” dual-energy X-ray absorptiometry (DEXA) scan in their early to mid-30s to help ...

Chinese drugmaker Guangzhou Innogen Pharmaceutical had a strong debut in Hong Kong, cashing in on positive sentiment toward its flagship drug and Chinese biotech stocks in general.

By Brooke Hudspeth, Pharm.D. University of Kentucky You’ve likely heard about glucagon-like peptide-1 agonists – usually ...

At least 500,000 people in the UK take either Mounjaro or Wegovy, another weight-loss jab, through private prescriptions ...